243 related articles for article (PubMed ID: 18786339)
21. Comparing incretin-based therapies. Evaluating GLP-1 agonists and DPP-4 inhibitors for type 2 diabetes mellitus.
Urquhart BS
Adv NPs PAs; 2010 Oct; 1(2):38-44. PubMed ID: 21299149
[No Abstract] [Full Text] [Related]
22. New treatments in type 2 diabetes: a focus on the incretin-based therapies.
Barnett AH
Clin Endocrinol (Oxf); 2009 Mar; 70(3):343-53. PubMed ID: 18771570
[TBL] [Abstract][Full Text] [Related]
23. The intersection of safety and adherence: new incretin-based therapies in patients with type 2 diabetes mellitus.
Zarowitz BJ; Conner C
Pharmacotherapy; 2009 Dec; 29(12 Pt 2):55S-67S. PubMed ID: 19947817
[TBL] [Abstract][Full Text] [Related]
24. Novel incretin-based agents and practical regimens to meet needs and treatment goals of patients with type 2 diabetes mellitus.
Garber AJ
J Am Osteopath Assoc; 2011 Jul; 111(7 Suppl 5):S20-30. PubMed ID: 21813733
[TBL] [Abstract][Full Text] [Related]
25. GPR119 agonists for the treatment of type 2 diabetes.
Jones RM; Leonard JN; Buzard DJ; Lehmann J
Expert Opin Ther Pat; 2009 Oct; 19(10):1339-59. PubMed ID: 19780700
[TBL] [Abstract][Full Text] [Related]
26. The effects of pharmacologic agents for type 2 diabetes mellitus on body weight.
Pi-Sunyer FX
Postgrad Med; 2008 Jul; 120(2):5-17. PubMed ID: 18654064
[TBL] [Abstract][Full Text] [Related]
27. Clinical application of incretin-based therapy: therapeutic potential, patient selection and clinical use.
Kendall DM; Cuddihy RM; Bergenstal RM
Eur J Intern Med; 2009 Jul; 20 Suppl 2():S329-39. PubMed ID: 19580952
[TBL] [Abstract][Full Text] [Related]
28. Incretin therapy for type 2 diabetes mellitus.
Klonoff DC
Adv Ther; 2010 Dec; 27(12):881-94. PubMed ID: 20978879
[TBL] [Abstract][Full Text] [Related]
29. Pharmacotherapy of hyperglycemia.
Kulasa KM; Henry RR
Expert Opin Pharmacother; 2009 Oct; 10(15):2415-32. PubMed ID: 19743938
[TBL] [Abstract][Full Text] [Related]
30. Comparing the actions of older and newer therapies on body weight: to what extent should these effects guide the selection of antidiabetic therapy?
Campbell IW
Int J Clin Pract; 2010 May; 64(6):791-801. PubMed ID: 20518953
[TBL] [Abstract][Full Text] [Related]
31. Incretin-based therapy: how do incretin mimetics and DPP-4 inhibitors fit into treatment algorithms for type 2 diabetic patients?
Nauck M; Smith U
Best Pract Res Clin Endocrinol Metab; 2009 Aug; 23(4):513-23. PubMed ID: 19748068
[TBL] [Abstract][Full Text] [Related]
32. Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitors.
Rizzo M; Rizvi AA; Spinas GA; Rini GB; Berneis K
Expert Opin Investig Drugs; 2009 Oct; 18(10):1495-503. PubMed ID: 19758106
[TBL] [Abstract][Full Text] [Related]
33. Confronting the type 2 diabetes epidemic: the emerging role of incretin-based therapies.
Fonseca VA; Zinman B; Nauck MA; Goldfine AB; Plutzky J
Am J Med; 2010 Jul; 123(7):S2-S10. PubMed ID: 20609666
[TBL] [Abstract][Full Text] [Related]
34. Overview of the gliptin class (dipeptidyl peptidase-4 inhibitors) in clinical practice.
Bohannon N
Postgrad Med; 2009 Jan; 121(1):40-5. PubMed ID: 19179812
[TBL] [Abstract][Full Text] [Related]
35. Antidiabetic effects of dipeptidyl peptidase-IV inhibitors and sulfonylureas in streptozotocin-nicotinamide-induced mildly diabetic mice.
Matsuyama-Yokono A; Tahara A; Nakano R; Someya Y; Shiraki K; Hayakawa M; Shibasaki M
Metabolism; 2009 Mar; 58(3):379-86. PubMed ID: 19217455
[TBL] [Abstract][Full Text] [Related]
36. Clinical application of incretin-based therapy: therapeutic potential, patient selection and clinical use.
Kendall DM; Cuddihy RM; Bergenstal RM
Am J Med; 2009 Jun; 122(6 Suppl):S37-50. PubMed ID: 19464427
[TBL] [Abstract][Full Text] [Related]
37. Sitagliptin 100 mg daily effect on DPP-4 inhibition and compound-specific glycemic improvement.
Alba M; Sheng D; Guan Y; Williams-Herman D; Larson P; Sachs JR; Thornberry N; Herman G; Kaufman KD; Goldstein BJ
Curr Med Res Opin; 2009 Oct; 25(10):2507-14. PubMed ID: 19691426
[TBL] [Abstract][Full Text] [Related]
38. [What can be expected from the GLP-1 agonists and DPP-4 inhibitors in the treatment of type 2 diabetes?].
Egli M; Ruiz J
Rev Med Suisse; 2007 Jun; 3(114):1449-50, 1453-5. PubMed ID: 17639666
[TBL] [Abstract][Full Text] [Related]
39. Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition.
Kirby M; Yu DM; O'Connor S; Gorrell MD
Clin Sci (Lond); 2009 Sep; 118(1):31-41. PubMed ID: 19780719
[TBL] [Abstract][Full Text] [Related]
40. Redefining treatment success in type 2 diabetes mellitus: Comprehensive targeting of core defects.
Cefalu WT; Richards RJ; Melendez-Ramirez LY
Cleve Clin J Med; 2009 Dec; 76 Suppl 5():S39-47. PubMed ID: 19952302
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]